Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2017 / Cilt: 27 - Sayı: 1

Parathyroid carcinoma case report: Rapid control of refractory hypercalcemia with denosumab

Paratiroid karsinomlu olgu sunumu: Dirençli hiperkalseminin denosumab ile hızlı kontrolü

Pages
57–60
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Denosumab may be considered as an alternative treatment agent with rapid efficiency in patients with severe hypercalcemia and parathyroid carcinoma

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Parathyroid carcinoma is a very rarely seen endocrine tumor which courses with severe hypercalcemia.
📊
Key Findings & Data:In this case report, we discussed the use of denosumab and other treatment approaches for a 44-year-old male patient diagnosed with parathyroid carcinoma who had a history of recurrent kidney stones, and evaluated with resistant and recurrent hypercalcemia.
💡
Conclusion & Impact:Denosumab may be considered as an alternative treatment agent with rapid efficiency in patients with severe hypercalcemia and parathyroid carcinoma
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Parathyroid carcinoma is a very rarely seen endocrine tumor which courses with severe hypercalcemia. Fluid replacement, diuretic therapy, bisphosphonates and calcimimetic agents are the main steps of the treatment in the control of lifethreatening hypercalcemia. There is limited information about the use of denosumab in recurrent and refractory hypercalcemia associated with parathyroid carcinoma. In this case report, we discussed the use of denosumab and other treatment approaches for a 44-year-old male patient diagnosed with parathyroid carcinoma who had a history of recurrent kidney stones, and evaluated with resistant and recurrent hypercalcemia. Normocalcemia could not be achieved during the follow-up after parathyroidectomy in the patient but rapid reduction of calcium was observed after the injection of denosumab. Denosumab may be considered as an alternative treatment agent with rapid efficiency in patients with severe hypercalcemia and parathyroid carcinoma

Özet

Paratiroid karsinomu hiperkalsemi ile seyreden ve çok ender görülen bir endokrin tümördür. Yaşamı tehdit eden hiperkalseminin kontrolünde sıvı replasmanı, diüretik tedavi, bifosfonatlar ve kalsimimetik ajanlar tedavinin ana basamağını oluşturmaktadır. Denosumabın paratiroid karsinomu ilişkili, dirençli ve yineleyen hiperkalsemilerde kullanımı ile ilgili bilgiler kısıtlıdır. Bu olgu sunumunda sık böbrek taşı öyküsü olan, dirençli ve yineleyen hiperkalsemi ile değerlendirilirken paratiroid karsinomu saptanan 44 yaşındaki erkek hastada tedavi yaklaşımı ve denosumab kullanımı tartışılmıştır. Paratiroidektomi ve sağ tiroid lobektomi sonrası takibinde normokalsemi sağlanamayan hastada denosumab enjeksiyonu sonrası hızlı kalsiyum düşüşü gözlenmiştir. Paratiroid karsinomu ve dirençli hiperkalsemisi olan olgularda denosumab hızlı etkinliğiyle diğer tedavilere alternatif bir ajan olarak değerlendirilebilir

🔖

Cite This Article

İLHAN, M., EKİNCİ, I., KARAMAN, Ö., TURGUT, S., TAŞAN, E. (2017). Parathyroid carcinoma case report: Rapid control of refractory hypercalcemia with denosumab. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 27 - Sayı: 1, 57–60. https://ajindex.com/articles/268363

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Lee PK, Jarosek SL, Virnig BA, Evasovich M, Tuttle TM. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 2007;109:1736-1741.
  2. Shane E. Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 2001;86:485-93.
  3. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH et al. Denosumab in postmenopa￾usal women with low bone mineral density. N Engl J Med 2006;354:821-831.
  4. Nadarasa K, Theodoraki A, Kurzawinski TR, Carpenter R, Bull J, Chung TT et al. Denosumab for management of ref￾ractory hypercalcaemia in recurrent parathyroid carcinoma. Eur J Endocrinol 2014;171:L7-8.
  5. Karuppiah D, Thanabalasingham G, Shine B, Wang LM, Sadler GP, Karavitaki N et al. Refractory hypercalcaemia secondary to parathyroid carcinoma: response to high-dose denosumab. Eur J Endocrinol 2014;171:K1-5.
  6. Vellanki P, Lange K, Elaraj D, Kopp PA, El Muayed M. Denosumab for management of parathyroid carcinoma￾mediated hypercalcemia. J Clin Endocrinol Metab 2014;99:387-390.
  7. Wei CH, Harari A. Parathyroid carcinoma: update and guideli￾nes for management. Curr Treat Options Oncol 2012;13:11-23.
  8. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM, Smallridge RC et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007;92:3803-3808.
  9. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813-822.
  10. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J et al. Randomized, double-blind study of denosu￾mab versus zoledronic acid in the treatment of bone metasta￾ses in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132.
  11. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advan￾ced breast c